Tekla Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Tekla Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$4.46M	Sell	411,101 -45,679	-10%	-$391K	0.17%	87
2023 Q1	$3.15M	Buy	+456,780	New	+$2.86M	0.12%	96
2019 Q2	–	Sell	-82,109	Closed	-$1.37M	–	203
2019 Q1	$1.37M	Sell	82,109 -106,835	-57%	-$1.54M	0.06%	145
2018 Q4	$2.17M	Buy	188,944 +104,887	+125%	+$2.12M	0.09%	124
2018 Q3	$3.36M	Buy	+84,057	New	+$2.39M	0.12%	116

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Tekla Capital Management's MRNS Position: Q2 2023 in Review

Tekla Capital Management reduced its Marinus Pharmaceuticals, Inc (MRNS) stake by 10% in Q2 2023, selling an estimated $391K and leaving 411,101 shares worth $4.46M. The position accounts for 0.17% of the portfolio, ranked #87.

Tekla Capital Management first reported a position in MRNS in Q3 2018 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold MRNS as of Q2 2023.

Tekla Capital Management held 411,101 shares of Marinus Pharmaceuticals, Inc worth $4.46M as of Q2 2023.
Tekla Capital Management sold 45,679 Marinus Pharmaceuticals, Inc shares in Q2 2023, an estimated $391K.
Marinus Pharmaceuticals, Inc made up 0.17% of Tekla Capital Management's portfolio in Q2 2023, its #87 holding.
Tekla Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and has held it in 5 quarters since.
106 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.